MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Chemotherapy

Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma

OncoTargets and Therapy 2017 June [Link] Aigner KR, Selak E, Gailhofer S Abstract INTRODUCTION: Therapy of malignant pleural mesothelioma and especially the adequate role of surgery in this context remain the subject of controversial discussions. Radical surgery in particular, which is associated with substantial morbidity, failed to translate into a definite survival advantage. We report […]

Comments Off on Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma

Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma

OncoTargets and Therapy 2017 June [Link] Aigner KR, Selak E, Gailhofer S Abstract INTRODUCTION: Therapy of malignant pleural mesothelioma and especially the adequate role of surgery in this context remain the subject of controversial discussions. Radical surgery in particular, which is associated with substantial morbidity, failed to translate into a definite survival advantage. We report […]

Comments Off on Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma

Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy

ESMO 2017 April [Link] Dolly SO, Migali C, Tunariu N, Della-Pepa C, Khakoo S, Hazell S, de Bono JS, Kaye SB, Banerjee S Abstract Peritoneal mesothelioma (MPeM) is a scarce abdominal-pelvic malignancy that presents with non-specific features and exhibits a wide clinical spectrum from indolent to aggressive disease. Due to it being a rare entity, […]

Comments Off on Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy

Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial

Lung Cancer 2017 August [Epub 2017 May 12] [Link] Zhan M, Zheng H, Xu T, Yang Y, Li Q Abstract PURPOSE: Malignant pleural mesothelioma (MPM) is a rare malignancy, and pemetrexed/cisplatin (PC) is the gold standard first-line regime. This study evaluated the cost-effectiveness of the addition of bevacizumab to PC (with maintenance bevacizumab) for unresectable […]

Comments Off on Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial

Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma

Expert Opinion of Investigational Drugs 2017 July 6 [Epub ahead of print] [Link] Guazzelli A, Bakker E, Tian K, Demonacos C, Krstic-Demonacos M, Mutti L Abstract INTRODUCTION: Malignant mesothelioma is a rare and lethal malignancy primarily affecting the pleura and peritoneum. Mesothelioma incidence is expected to increase worldwide and current treatments remain ineffective, leading to […]

Comments Off on Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma

JQ1, a BET inhibitor, synergizes with cisplatin and induces apoptosis in highly chemoresistant malignant pleural mesothelioma cells

Current Cancer Drug Targets 2017 June 23 [Epub ahead of print] [Link] Zanellato I, Colangelo D, Osella D Abstract Malignant pleural mesothelioma (MPM) is an asbestos-associated tumor with poor prognosis and few therapeutic options. JQ1, a selective antagonist of BRD4, modulates transcription of oncogenes, including MPM chemoresistance-associated c-Myc and Fra-1. We investigated if JQ1 could […]

Comments Off on JQ1, a BET inhibitor, synergizes with cisplatin and induces apoptosis in highly chemoresistant malignant pleural mesothelioma cells

Pro-oxidant activity of sulforaphane and cisplatin potentiates apoptosis and simultaneously promotes autophagy in malignant mesothelioma cells

Molecular Medicine Reports 2017 June [Epub ahead of print] [Link] Lee YJ, Lee SH Abstract Sulforaphane (SFN) is an isothiocyanate compound derived from glucoraphanin, which is found in cruciferous vegetables, and has been heralded as a chemopreventive and/or chemotherapeutic agent. The present study investigated the effects of SFN on enhancing the anticancer role of cisplatin […]

Comments Off on Pro-oxidant activity of sulforaphane and cisplatin potentiates apoptosis and simultaneously promotes autophagy in malignant mesothelioma cells

Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma

Expert review of respiratory medicine 2017 June [Epub ahead of print] [Link] Marulli G, Faccioli E, Bellini A, Mammana M, Rea F Abstract INTRODUCTION: Malignant pleural mesothelioma (MPM) is an aggressive neoplasia. Multidisciplinary treatments, including the association of induction and/or adjuvant therapeutic regimens with surgery, have been reported to give encouraging results. Current therapeutic options […]

Comments Off on Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma

First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma

Expert review of anticancer therapy 2017 June 8 [Epub ahead of print] [Link] Fujimoto E, Kijima T, Kuribayashi K, Negi Y, Kanemura S, Mikami K, Doi H, Kitajima K, Nakano T Abstract BACKGROUND: Mesothelioma of peritoneal origin has wider variation in treatment outcomes than mesothelioma of pleural origin, likely because peritoneal mesothelioma comprises borderline malignant […]

Comments Off on First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma

Phase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma (SWOG S0905)

Journal of Thoracic Oncology 2017 June 6 [Epub ahead of print] [Link] Tsao AS, Moon J, Wistuba II, Vogelzang NJ, Kalemkerian GP, Redman MW, Gandara DR, Kelly K Abstract BACKGROUND: In malignant pleural mesothelioma (MPM), targeting angiogenesis, with cediranib, a vascular endothelial growth factor receptor (VEGFR) and platelet derived growth factor receptor (PDGFR) inhibitor, may […]

Comments Off on Phase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma (SWOG S0905)